Literature DB >> 24425115

Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.

Ritvij Bowry1, Stuart Fraser, Joancy M Archeval-Lao, Stephanie A Parker, Chunyan Cai, Mohammad H Rahbar, James C Grotta.   

Abstract

BACKGROUND AND
PURPOSE: Factor Xa inhibitors are prescribed for stroke prevention in atrial fibrillation. Managing such patients is challenging especially if they are eligible for thrombolysis because there is no rapidly available test to detect the effect of such medications. Thrombelastography analyzes the dynamics of coagulation and can be rapidly performed. We sought to determine whether thrombelastography can detect the anticoagulation effect of factor Xa inhibitors in patients with stroke.
METHODS: Blood from 10 patients with stroke was analyzed by thrombelastography at baseline and 2 to 18 hours after rivaroxaban administration.
RESULTS: Increased R, K, and δ were seen at 2, 4, and 6 hours, while G, maximum amplitude, α-angle, and LY30 were decreased. Baseline R was 5.8±0.5 when compared with 11.4±1.0 at 2 hours. R remained prolonged at 18 hours. Other thrombelastography parameters were normal by 18 hours.
CONCLUSIONS: Thrombelastography can detect the anticoagulant effect of factor Xa inhibitors in patients with stroke and might be useful in the emergency management of those eligible for thrombolysis.

Entities:  

Keywords:  factor Xa; rivaroxaban; stroke; thrombolytic therapy

Mesh:

Substances:

Year:  2014        PMID: 24425115      PMCID: PMC3954973          DOI: 10.1161/STROKEAHA.113.004016

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

Review 1.  Thrombelastography.

Authors:  S V Mallett; D J Cox
Journal:  Br J Anaesth       Date:  1992-09       Impact factor: 9.166

2.  Facts and artefacts of coagulation assays for factor Xa inhibitors.

Authors:  Sylvia Haas
Journal:  Thromb Haemost       Date:  2010-02-19       Impact factor: 5.249

3.  Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Meyer Michel Samama; Jean-Luc Martinoli; Léna LeFlem; Céline Guinet; Geneviève Plu-Bureau; François Depasse; Elisabeth Perzborn
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

4.  Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™.

Authors:  M Casutt; C Konrad; G Schuepfer
Journal:  Anaesthesist       Date:  2012-10-07       Impact factor: 1.041

5.  Thromboelastography in patients with acute ischemic stroke.

Authors:  Andrea Elliott; Jeremy Wetzel; Tiffany Roper; Evan Pivalizza; James McCarthy; Cristina Wallace; Mary Jane Hess; Hui Peng; Mohammad H Rahbar; Navdeep Sangha; James C Grotta
Journal:  Int J Stroke       Date:  2012-09-27       Impact factor: 5.266

6.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

  6 in total
  9 in total

Review 1.  Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.

Authors:  Sujan T Reddy; T C Cossey; Sean I Savitz; James C Grotta
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 2.  Emergency reversal of anticoagulation: novel agents.

Authors:  Michael Levine; Joshua N Goldstein
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

3.  In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.

Authors:  Mareike K Körber; Elisabeth Langer; Lutz Kaufner; Michael Sander; Christian Von Heymann
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

Review 4.  Reversal of anticoagulant effects in patients with intracerebral hemorrhage.

Authors:  Sean Yates; Ravi Sarode
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

5.  Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.

Authors:  Maria Cristina Vedovati; Maria Giulia Mosconi; Federico Isidori; Giancarlo Agnelli; Cecilia Becattini
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

6.  A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.

Authors:  Rami A Al-Horani; Elsamani I Abdelfadiel; Daniel K Afosah; Shravan Morla; Jyothi C Sistla; Bassem Mohammed; Erika J Martin; Masahiro Sakagami; Donald F Brophy; Umesh R Desai
Journal:  J Thromb Haemost       Date:  2019-09-10       Impact factor: 5.824

7.  Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.

Authors:  A Y Mehta; B M Mohammed; E J Martin; D F Brophy; D Gailani; U R Desai
Journal:  J Thromb Haemost       Date:  2016-02-16       Impact factor: 5.824

Review 8.  Global assays of hemostasis.

Authors:  Kathleen E Brummel-Ziedins; Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

9.  A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs.

Authors:  Liam A Evans; Colleen Tansey; Melissa Wiebe; Caroline Q Sloan; Jeffrey E Patlogar; Sarah Northcutt; Lisa A Murphy; Reid K Nakamura
Journal:  Vet Med Sci       Date:  2019-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.